KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.95

Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.

April W Armstrong, Mark Lebwohl, Richard B Warren, Howard Sofen, Akimichi Morita, Carle Paul, Kim A Papp, Matthew J Colombo, Julie Scotto, John Vaile, Joe Zhuo, Eleni Vritzali, Victoria Berger, Georgene Schroeder, Subhashis Banerjee, Diamant Thaçi, Bruce Strober

J Eur Acad Dermatol Venereol 39(7) 1336-1351

PMID40045918
PMCIDPMC12188513
DOI10.1111/jdv.20553
发表日期2025-03-06
入排依据:Study is a Phase 3 randomized trial of deucravacitinib in plaque psoriasis (non-oncology) with drug intervention and original results, but lacks a primary/key secondary time-to-event efficacy endpoint as required for the cohort.
摘要

摘要

BACKGROUND: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. OBJECTIVES: To evaluate the safety and efficacy of deucravacitinib through 4 years in the Phase 3 POETYK PSO-1, PSO-2 and long-term extension (LTE) trials in psoriasis. METHODS: PSO-1 and PSO-2 (parent trials) randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily (QD) or apremilast 30 mg twice daily. At 52 weeks, patients enrolled in the LTE trial received open-label deucravacitinib 6 mg QD. Safety was evaluated in patients who received ≥1 dose of deucravacitinib at any time. Clinical and patient-reported outcomes (PASI, PGA and DLQI) were analysed in patients who received continuous deucravacitinib from Day 1 of the parent trials and enrolled in the LTE trial. RESULTS: In total, 1519 patients received ≥1 dose of deucravacitinib, with cumulative exposure of 4392.8 person-years (PY) through the data cut-off of 1 November 2023. Exposure-adjusted incidence rates (EAIRs)/100 PY of noted safety measures were comparable or decreased from the 1-year to 4-year cumulative period, respectively, for adverse events (AEs) (229.23, 131.68), serious AEs (including COVID-19) (5.68, 5.01), deaths (0.20, 0.25), discontinuation due to AEs (4.38, 2.20), herpes zoster (0.81, 0.55), malignancies (1.02, 0.89), major adverse cardiovascular events (0.30, 0.32) and venous thromboembolism (0.20, 0.07). In patients who received continuous deucravacitinib (n = 513), clinical and patient-reported outcome rates were well maintained from 1 year through 4 years (e.g. PASI 90, 1 year, 45.6% [95% CI, 41.3%-50.0%], 4 years, 47.5% [42.6%-52.4%]; DLQI 0/1, 1 year, 51.5% [47.1%-55.9%], 4 years, 49.4% [44.4%-54.4%]). CONCLUSIONS: Deucravacitinib demonstrated a consistent safety profile and durable efficacy through 4 years of treatment in patients with moderate to severe plaque psoriasis.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

FIGURE 5

(a) ss‐PGA 0/1 and (b) PGA‐F 0/1 response rates with continuous deucravacitinib treatment from Day 1–4 years. Data callouts represent the response rate (95% CI). CI, confidence interval; LTE, long‐term extension; mNRI, modified nonresponder imputation; PGA‐F, Physician Global Assessment‐Fingernail; ss‐PGA, scalp‐specific Physician Global Assessment; TFR, treatment failure rules.

_a_

ss‐PGA 0/1 response rates

FIGURE 5 · Panel _a_

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel _a_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 1 条曲线 1:off origin start曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
_b_

PGA‐F 0/1 response rates

FIGURE 5 · Panel _b_

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel _b_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1The POETYK PSO‐1, PSO‐2 and LTE study designs. a Apremilast was titrated from 10 mg QD to 30 mg BID over the first 5 days of dosing. b Upon relapse (≥50% loss of Week 24 PASI percentage improvement from baseline), patients were to be switched to deucravacitinib 6 mg QD; due to a programming error, however, these patients continued on placebo until Week 52. c Data reported through the 208‐day POETYK LTE cut‐off date of 1 November 2023. Reproduced with permission from Lebwohl M, et al. 12 BID, twice daily; LTE, long‐term extension; PASI 50/75, ≥50%/≥75% reduction from baseline in Psoriasis Area and Severity Index; QD, once daily.
非 KM Figure
FIGURE 2Changes in haematology, chemistry and lipid parameters (a‐l) over 4 years in patients receiving deucravacitinib. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; LLN, lower limit of normal; LTE, long‐term extension; SD, standard deviation; ULN, upper limit of normal.
非 KM Figure
FIGURE 3Clinical efficacy outcomes through 4 years. (a) PASI 75. (b) PASI 90. (c) PASI 100. (d) sPGA 0/1. (e) sPGA 0. Data callouts represent response rate (95% CI). CI, confidence interval; LTE, long‐term extension; mNRI, modified nonresponder imputation; PASI 75/90/100, ≥75%/≥90%/100% reduction from baseline in Psoriasis Area and Severity Index; sPGA 0/1, static Physician Global Assessment score of 0 (clear) or 1 (almost clear) with a ≥ 2‐ point improvement from baseline; TFR, treatment failure rules.
非 KM Figure
FIGURE 4Adjusted mean per cent change from baseline in PASI score through 4 years with MI‐BOCF imputation. Data callouts represent mean percent change from baseline (95% CI). CI, confidence interval; LTE, long‐term extension; MI‐BOCF, baseline observation carried forward with multiple imputation; PASI, Psoriasis Area and Severity Index; SD, standard deviation.
非 KM Figure
FIGURE 6PSSD total score change from baseline with continuous deucravacitinib treatment through 4 years. Data from Weeks 0–52 reflect the weekly average of daily scores using the 24‐hour recall PSSD. Weeks 68–196 reflect the 7‐day recall PSSD score. Patient‐reported outcomes were recorded on a different schedule than clinical efficacy and safety outcomes; therefore, they are reported through Week 196 (the closest timepoint to Week 208). Data callouts represent mean score change from baseline (95% CI). CI, confidence interval; LTE, long‐term extension; MI‐BOCF, baseline observation carried forward with multiple imputation; PSSD, Psoriasis Symptoms and Signs Diary; SD, standard deviation.
非 KM Figure
FIGURE 7DLQI 0/1 response rate with continuous deucravacitinib treatment through 4 years in patients with parent study baseline DLQI ≥2. Patient‐reported outcomes were recorded on a different schedule than clinical efficacy and safety outcomes; therefore, they are reported through Week 196 (the closest timepoint to Week 208). Data callouts represent response rate (95% CI). CI, confidence interval; DLQI 0/1, Dermatology Life Quality Index of 0 or 1; LTE, long‐term extension; mNRI, modified nonresponder imputation.
非 KM Figure
FIGURE 8Incidence rates of AEs of interest (a‐c), deucravacitinib versus other systemic psoriasis treatments. The deucravacitinib data represent the phase 3 safety pool through the LTE cut‐off date of 01 November 2023. Published data on malignancies excluding NMSC were not available for secukinumab. Incidence rates for patients with psoriasis stratified by therapy are from the Optum Claims Analysis; data on file [Bristol Myers Squibb, 2024]. BADBIR, British Association of Dermatologists Biologic and Immunomodulators Register; CI, confidence interval; EAIR, exposure‐adjusted incidence rate; IL, interleukin; LTE, long‐term extension; MACE, major adverse cardiovascular event; NMSC, nonmelanoma skin cancer; PsoBest, the German Psoriasis Registry; PSOLAR, the Psoriasis Longitudinal Assessment and Registry; PY, person‐years; SEER, Surveillance, Epidemiology, and End Results programme; TNF, tumour necrosis factor.
非 KM Figure